Slideshow
Author(s):
New Parkinson disease studies offer insights into topics such as LRRK2 G2019S transgene activity, preclinical drug development, and neuroprotection in Parkinson disease.
Multiple System Atrophy Agent ATH434 Shows Promising Topline Efficacy in Phase 2 Trial